Australia's Nyrada rises on encouraging efficacy results from cholesterol drug study

Nyrada

29/06/2021 04:14

** Shares of drug developer Nyrada Inc  NYR.AX  jump as much
as 8.6% to A$0.315, marking their best day since June 8
    ** Co announces encouraging efficacy results from a
preclinical study of its oral inhibitor treatment for high
cholesterol, NYX-PCSK9i in a specialised mouse model
 urn:newsml:reuters.com:*:nFWN2OA0Y4
    ** Says results from the preclinical efficacy study showed
NYX-PCSK9i reduced total cholesterol by 46% as a monotherapy,
and 65% when dosed in combination with the statin drug Lipitor
over the study period
    ** Says no adverse effects were identified and NYX-PCSK9i
was well-tolerated
    ** Adds that safety pharmacology and toxicology studies of
NYX-PCSK9i will commence in H2 2021 in preparation for a Phase I
first-in-human study, which is set to commence mid-2022
    ** Stock hits highest since June 16
    ** Stock up 20.8% so far this year, as of last close 
    


 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))